Nakajima Yasuaki, Kawada Kenro, Tokairin Yutaka, Hoshino Akihiro, Okada Takuya, Kawano Tatsuyuki
Department of Esophageal Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
Dig Surg. 2018;35(2):131-137. doi: 10.1159/000477265. Epub 2017 May 30.
BACKGROUND/AIMS: This study documents the clinical efficacy and toxicity of S-1 and paclitaxel (S1/PTX) in patients with unresectable or postoperative recurrent esophageal squamous cell carcinoma (ESCC) who had been previously treated with fluorouracil (5FU), cisplatin, and docetaxel.
Twenty-eight ESCC patients treated using S1/PTX at our institute since 2010 were enrolled in this study. S1 was administered orally at a dose of 80 mg/m2/day from days 1 to 14, and PTX was administered intravenously on days 1 and 8 at a dose of 80-100 mg/m2.
A total of 106 cycles (median 2.5 cycles, range 1-12 cycles) were administered. The response rate was 14.8%, including 3 complete responses. The median progression-free survival time was 137 days, and the median overall survival time was 306 days. Severe neutropenia occurred in 13 patients, and 3 showed febrile neutropenia. All non-hematological toxicities were mild, and peripheral nerve paralysis was observed in 2 patients.
S1/PTX was found to have tolerable clinical efficacy in terms of the response rate, survival and toxicity in patients with unresectable or postoperative recurrent ESCC who had previously been treated with 5FU, cisplatin, and docetaxel.
背景/目的：本研究记录了S-1与紫杉醇（S1/PTX）联合用药对不可切除或术后复发的食管鳞状细胞癌（ESCC）患者的临床疗效及毒性，这些患者此前已接受过氟尿嘧啶（5FU）、顺铂和多西他赛治疗。
自2010年起，在我院接受S1/PTX治疗的28例ESCC患者纳入本研究。S1于第1至14天口服给药，剂量为80mg/m²/天，PTX于第1天和第8天静脉给药，剂量为80 - 100mg/m²。
共进行了106个周期（中位周期数2.5个，范围1 - 12个周期）的治疗。总缓解率为14.8%，包括3例完全缓解。中位无进展生存期为137天，中位总生存期为306天。13例患者出现严重中性粒细胞减少，3例出现发热性中性粒细胞减少。所有非血液学毒性均较轻，2例患者出现周围神经麻痹。
对于先前接受过5FU、顺铂和多西他赛治疗的不可切除或术后复发的ESCC患者，S1/PTX在缓解率、生存期和毒性方面具有可耐受的临床疗效。
